EACR The Tumour Ecosystem: Cellular Interactions & Therapeutic Opprtunities

Join us to hear from world experts who are at the forefront of the tumour microenvironment field, sharing their latest discoveries and insights about this cutting-edge research and its implications for novel cancer therapies. Featured topics include the role of inflammation and immunity in tumour progression and metastasis, organ-specific stromal cells that support tumour progression, metabolic changes in the tumour microenvironment, tumour-host interactions in response to therapy, cancer interactions with the nervous system, and dormancy and metastasis. 

The target audience for this conference is: scientists, postdocs, and graduate students interested in multiple aspects of cancer biology, immunology, and therapeutics; industry scientists interested in translational research and novel therapeutic approaches; and journal editors interested in cutting-edge cancer biology.

Speakers: Leila Akkari (Netherlands Cancer Institute, Netherlands), Jean Albrengues (Université Côte d’Azur, France), Adrienne Boire (Memorial Sloan Kettering Cancer Center, USA), Karin de Visser (NKI Amsterdam, Netherlands), Neta Erez (Tel Aviv University, Israel), Doug Hanahan (Ludwig Cancer Research, Switzerland), Clare Isacke (ICR, UK), Mariam Jamal-Hanjani (UCL, UK), Johanna Joyce (University of Lausanne, Switzerland), Erik Sahai (The Francis Crick Institute, UK), Ruth Scherz-Shouval (Weizmann Institute, Israel), Yuval Shaked (Tenion – Israel Institute of Technology, Israel), Mariia Yuneva (The Francis Crick Institute, UK), and Sara Zanivan (CRUK Beatson Institute, UK)

Keywords: tumour ecosystem, carcinogenesis, metastasis, tumour therapy response, novel therapeutics, reciprocal cancer-stroma interactions, tumour progression, organ-specific stromal cells, tumour-host interactions, nervous system interactions, tumour dormancy, metastasis progression, ECM remodelling, therapy resistance, immune cell heterogeneity, stromal plasticity, immune plasticity, fibroblast interactions, treatment resistance, cancer research, oncology